
KEYNOTE-029: Alternate Doses of Ipilimumab Show Similar Results in Advanced Melanoma
Researchers tested standard-dose pembrolizumab plus ipilimumab at 50-mg or 100-mg doses in patients with previously untreated advanced melanoma.
CHICAGO-Standard-dose pembrolizumab plus ipilimumab at 50-mg and 100-mg doses showed robust, durable antitumor activity in patients with previously untreated advanced melanoma, according to the results of the KEYNOTE-029 cohort 1C (
Cohort 1B of the KEYNOTE-029 trial previously demonstrated that standard-dose pembrolizumab plus 4 doses of ipilimumab 1 mg/kg was more efficacious and had lower rates of grade 3–5 toxicity compared with standard-dose nivolumab plus ipilimumab in patients with advanced melanoma.
“I think we are seeing some signals [from immunotherapy in general] that we can be confident about discussing with our patients in the clinic,” said
For KEYNOTE-029 cohort 1C, the investigators assessed the toxicity and antitumor activity of standard-dose pembrolizumab combined with either 50 mg or 100 mg of ipilimumab in patients with advanced melanoma. For inclusion, patients were required to have previously untreated stage III/IV melanoma, ECOG performance scores of 0 to 1, and no active central nervous system metastases. The primary endpoints were grade 3–5 treatment-related adverse event rate and objective response rate (ORR).
In total, 102 patients with a median age of 63.5 years were included (men, 70%; women, 30%). Patients were randomized to receive pembrolizumab (200 mg every 3 weeks for 24 months) plus 4 doses of ipilimumab 50 mg every 6 weeks, or pembrolizumab plus 4 doses of ipilimumab 100 mg every 12 weeks. Each arm was assigned 51 patients.
At a median follow-up of approximately 16 months, 59% of patients in the 50-mg ipilimumab arm and 47% of patients in the 100-mg ipilimumab arm remained on treatment. In the 50-mg ipilimumab arm and 100-mg ipilimumab arm, 41% and 47% of patients discontinued all treatment, respectively. The treatment-related adverse event rate for at least one event of all grades was 100% in the 50-mg ipilimumab arm and 96% in the 100-mg ipilimumab arm. The grade 3–5 treatment-related adverse event rate was 24% (10% immune-related) in the 50-mg ipilimumab arm and 39% (22% immune-related) in the 100-mg ipilimumab arm. A single patient, who was in the 50-mg ipilimumab arm, had a grade 5 event (autoimmune myocarditis).
The ORR was 55% (95% CI, 40%–69%) in the 50-mg ipilimumab arm and 61% (95% CI, 46%–74%) in the 100-mg ipilimumab arm. The disease control rate was 78% (95% CI, 65%–89%) and 86% (95% CI, 74%–94%), respectively. The median time to response was similar between the two groups (1.4 months vs 1.5 months). An ongoing response was observed in 71% of the patients in the 50-mg ipilimumab arm and 87% of patients in the 100-mg ipilimumab arm. Progression-free survival and overall survival were not yet reached.
The discussant for the study,
Related to this article








